Business Context and Reporting Period
This Form 8-K Current Report is filed by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) on June 10, 2026. The report details a material corporate action regarding the company's capital structure, specifically the implementation of a reverse stock split approved by stockholders at the annual meeting held on May 21, 2026.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the administrative and structural details of the reverse stock split.
Material Changes
- Reverse Stock Split Execution: The Board of Directors approved a one-for-ten (1:10) reverse stock split on June 1, 2026. The split became effective at the start of trading on June 11, 2026.
- Share Reclassification: Every ten (10) shares of issued and outstanding Common Stock immediately prior to the effective time were automatically reclassified into one (1) share.
- Adjustment of Convertible Securities: The number of shares issuable upon the exercise or vesting of outstanding warrants, restricted stock units, and convertible preferred stock was reduced proportionately. Correspondingly, the exercise or conversion prices of these securities were increased proportionately.
- Fractional Shares: No fractional shares were issued. Stockholders entitled to a fractional share received one full share of post-split Common Stock in lieu thereof.
- Trading Information: Trading resumed on The Nasdaq Capital Market on a split-adjusted basis on June 11, 2026, under the new CUSIP number 825693500.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the standard disclosure that the description of the Certificate of Amendment is qualified by reference to the full text filed as Exhibit 3.1. The primary purpose of the filing is to disclose the amendment to the Articles of Incorporation and the change in rights of security holders.
Investor Verification Checklist
- Verify the new CUSIP number (825693500) for trading purposes.
- Confirm the adjusted number of shares held in brokerage accounts following the 1:10 split.
- Review the adjusted exercise prices and share counts for any outstanding warrants, RSUs, or convertible preferred stock.
- Check the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.